![](/-/media/icons/2019/pharma/biomedtracker-icon.png?rev=fc7926a0385c4901b67c1887d9aac276)
Forest pays $240mm up front for exclusive US rights to Merck's Saphris
Executive Summary
Spec pharma Forest Laboratories Inc. (CNS, cardiovascular, GI, respiratory, and infectious disease therapies) paid $240mm up front for exclusive US rights to Merck & Co. Inc.’s antipsychotic drug Saphris (asenapine). Forest could also pay undisclosed sales milestones.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice